AbbVie Completes $10.9B Acquisition of Apogee; APGE to Delist September 4
APGE has more than doubled off its 52-week low of $35.39 on elevated volume (1.8× avg).
Summary
AbbVie completed its $10.9 billion all-cash acquisition of Apogee Therapeutics on September 3, 2026. APGE shares will be suspended from Nasdaq trading on September 4, 2026.
Key Events · M&A and Partnerships · APGE
-
Merger Consummated
Merger Sub merged with and into Apogee on September 3, 2026, making Apogee an indirect wholly owned subsidiary of AbbVie. Total equity value was approximately $10.9 billion.
-
Shareholders Receive $135.11 Per Share
Each outstanding share of common stock was cancelled and converted into the right to receive $135.11 in cash, without interest and subject to tax withholding.
-
Nasdaq Delisting Initiated
Trading in APGE will be suspended on September 4, 2026. The company will file Form 25 to delist and Form 15 to terminate registration and reporting obligations.
-
Board and Officers Replaced
All seven Apogee directors resigned effective at the merger's effective time, replaced by Merger Sub directors. All executive officers ceased serving in their positions.
Analysis · APGE · Life Sciences
The AbbVie acquisition of Apogee Therapeutics has closed. Every outstanding share was converted into the right to receive $135.11 in cash, and the company is now an indirect wholly owned subsidiary of AbbVie. Trading in APGE will be suspended on September 4, 2026, with delisting and deregistration to follow. This is the final step in a deal that was announced in June and approved by stockholders in August — the thesis for Apogee shareholders is now fully resolved at the agreed price.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 41.8% of the 507 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, APGE was trading at $135.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.2B. The 52-week trading range was $35.39 to $135.09. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.